FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306750003> ?p ?o ?g. }

• W4306750003 endingPage "363" @default.
• W4306750003 startingPage "357" @default.
• W4306750003 abstract "Abstract In recent years, the development of combination therapies with immune checkpoint inhibitors (ICIs) and cytotoxic anticancer drugs has radically changed the management of diverse malignancies and significantly improved patient outcomes. Several clinical trials have shown that skin rash caused by combination therapy with ICIs and cytotoxic drugs may be more frequent and severe than that developing after administration of ICIs alone or cytotoxic drug monotherapy. However, most reports provide little information on severity, treatment, post‐diagnosis course, and recurrence of rashes on drug rechallenges. We aimed to describe the experience of skin rashes developing within 2 weeks from the first administration of combination therapy with ICIs and cytotoxic drugs in 11 patients visiting our dermatology department. This study included seven men and four women, and the patients' median age was 52 years. The primary disease was non‐small‐cell lung cancer in eight patients, cervical cancer in two patients, and esophageal cancer in one patient. Nine patients had a maculopapular rash and two patients developed erythema multiforme‐like eruptions. The skin rash was often accompanied by extracutaneous symptoms, such as fever ( n = 9), mucositis ( n = 4), and liver dysfunction ( n = 2). In all cases, the symptoms improved with topical steroid therapy alone, with no patients exhibiting severe symptoms requiring systemic steroids or immunosuppressive agents. In addition, when the causative drugs were re‐administered after recovery from the rash, only two patients relapsed with accompanying systemic symptoms, and all patients except one were able to continue treatment using the same drug regimen. Although it was suggested that the rash caused by the combination therapy of ICIs and cytotoxic drugs may be more prominent than that caused by each agent alone, comprehensive judgment, including histopathological examination, may indicate the feasibility of continuing the treatment regimen for cancer." @default.
• W4306750003 created "2022-10-19" @default.
• W4306750003 creator A5023606171 @default.
• W4306750003 creator A5026903960 @default.
• W4306750003 creator A5041519025 @default.
• W4306750003 creator A5059079744 @default.
• W4306750003 creator A5074992683 @default.
• W4306750003 date "2022-10-18" @default.
• W4306750003 modified "2023-10-17" @default.
• W4306750003 title "Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single‐center case series" @default.
• W4306750003 cites W1482371792 @default.
• W4306750003 cites W2507809600 @default.
• W4306750003 cites W2906436263 @default.
• W4306750003 cites W2986633517 @default.
• W4306750003 cites W3017322331 @default.
• W4306750003 cites W3027845041 @default.
• W4306750003 cites W3082736986 @default.
• W4306750003 cites W3099334277 @default.
• W4306750003 cites W3109853980 @default.
• W4306750003 cites W3195935456 @default.
• W4306750003 doi "https://doi.org/10.1111/1346-8138.16614" @default.
• W4306750003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36258256" @default.
• W4306750003 hasPublicationYear "2022" @default.
• W4306750003 type Work @default.
• W4306750003 citedByCount "0" @default.
• W4306750003 crossrefType "journal-article" @default.
• W4306750003 hasAuthorship W4306750003A5023606171 @default.
• W4306750003 hasAuthorship W4306750003A5026903960 @default.
• W4306750003 hasAuthorship W4306750003A5041519025 @default.
• W4306750003 hasAuthorship W4306750003A5059079744 @default.
• W4306750003 hasAuthorship W4306750003A5074992683 @default.
• W4306750003 hasConcept C121608353 @default.
• W4306750003 hasConcept C126322002 @default.
• W4306750003 hasConcept C16005928 @default.
• W4306750003 hasConcept C197934379 @default.
• W4306750003 hasConcept C2776256026 @default.
• W4306750003 hasConcept C2776694085 @default.
• W4306750003 hasConcept C2778168870 @default.
• W4306750003 hasConcept C2778496288 @default.
• W4306750003 hasConcept C2778570526 @default.
• W4306750003 hasConcept C2781320243 @default.
• W4306750003 hasConcept C2781413609 @default.
• W4306750003 hasConcept C71924100 @default.
• W4306750003 hasConceptScore W4306750003C121608353 @default.
• W4306750003 hasConceptScore W4306750003C126322002 @default.
• W4306750003 hasConceptScore W4306750003C16005928 @default.
• W4306750003 hasConceptScore W4306750003C197934379 @default.
• W4306750003 hasConceptScore W4306750003C2776256026 @default.
• W4306750003 hasConceptScore W4306750003C2776694085 @default.
• W4306750003 hasConceptScore W4306750003C2778168870 @default.
• W4306750003 hasConceptScore W4306750003C2778496288 @default.
• W4306750003 hasConceptScore W4306750003C2778570526 @default.
• W4306750003 hasConceptScore W4306750003C2781320243 @default.
• W4306750003 hasConceptScore W4306750003C2781413609 @default.
• W4306750003 hasConceptScore W4306750003C71924100 @default.
• W4306750003 hasIssue "3" @default.
• W4306750003 hasLocation W43067500031 @default.
• W4306750003 hasLocation W43067500032 @default.
• W4306750003 hasOpenAccess W4306750003 @default.
• W4306750003 hasPrimaryLocation W43067500031 @default.
• W4306750003 hasRelatedWork W2113120342 @default.
• W4306750003 hasRelatedWork W2557912444 @default.
• W4306750003 hasRelatedWork W2759039518 @default.
• W4306750003 hasRelatedWork W3099334277 @default.
• W4306750003 hasRelatedWork W3137546391 @default.
• W4306750003 hasRelatedWork W3196418556 @default.
• W4306750003 hasRelatedWork W3196645532 @default.
• W4306750003 hasRelatedWork W4223913319 @default.
• W4306750003 hasRelatedWork W4285404370 @default.
• W4306750003 hasRelatedWork W4387217931 @default.
• W4306750003 hasVolume "50" @default.
• W4306750003 isParatext "false" @default.
• W4306750003 isRetracted "false" @default.
• W4306750003 workType "article" @default.